News & Updates
Filter by Specialty:
Ipilimumab plus nivolumab elicits response in mCRPC
Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).
Ipilimumab plus nivolumab elicits response in mCRPC
02 Jan 2025
Cuffless device may revolutionize hypertension management
A retrospective analysis shows that continual cuffless blood pressure (BP) monitoring may facilitate rapid and practical assessment of systolic BP (SBP) time-in-target range (TTR), an emerging metric of hypertension control.
Cuffless device may revolutionize hypertension management
02 Jan 2025
NT-proBNP predicts cardiorenal complications in Chinese patients with T2D
Elevated N-terminal pro–B-type natriuretic peptide (NT-proBNP) levels independently predict cardiorenal complications in Chinese patients with type 2 diabetes (T2D) and can be utilized as a clinical prognostic biomarker for risk stratification to enable more intensive organ-protective treatment in those at risk, a study involving 1,993 patients enrolled in the Hong Kong Diabetes Biobank has shown.
